Tribe-owned company's USAID contracts among those axed by DOGE
Mashantucket — Two contracts a Mashantucket Pequot-owned company had with the U.S. Agency for International Development are among the thousands of government contracts the Elon Musk-led Department of Government Efficiency, or DOGE, has terminated.
The contracts, which had been held by CeLeen LLC, an information technology company, totaled $106.7 million. They were canceled last month.
'We did have contracts terminated 'for convenience' — the government's convenience,' said Jon Panamaroff, chief executive officer of Command Holdings, the tribal holding company that acquired CeLeen in 2021. 'We're trying to be tight-lipped about this,' he said, declining to discuss details of the contracts or DOGE.
'Contracts come, contracts go,' Panamaroff said. 'We had diversified well in both the commercial and private sectors. We have other contracts ... and we want to do more business with the government.'
CeLeen offers a variety of IT and professional services.
One of the canceled contracts had a total value of $82.4 million and was for 'institutional support services for USAID/OTI operations and programs.' OTI refers to USAID's Office of Transition Initiative, which 'focuses on supporting political transitions and stabilization efforts in response to political crises,' according to a description on the website HigherGov.com, which tracks the government contracting and grant markets.
CeLeen's other canceled contract, with a total value of about $24.3 million, was for 'administrative and technical support for DRG (democracy, human rights and governance) offices and projects.'
The Mashantuckets, owners of Foxwoods Resort Casino, launched Command Holdings amid the COVID-19 pandemic, which caused the casino to close for 11 weeks in 2020 and focused the tribe's attention on its need to diversify.
'We're here to build a network of companies involved in federal and private, commercial contracting,' Panamaroff said at the time. 'The federal government sends out billions of dollars worth of business to companies, and tribes have the ability to participate in that marketplace.'
Command Holdings also acquired Washington, D.C.-based Quattro Publishing in 2021 and the next year added WWC Global, a woman-owned consulting firm. WWC's clients included the Departments of Defense, State and Homeland Security as well as USAID. Command also owns Copperhead Technologies, a computer programming and systems design company.
On Friday, DOGE's website said the agency has so far terminated 5,634 contracts, generating about $20 billion in savings.
b.hallenbeck@theday.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
America's Car-Mart (NASDAQ:CRMT) Delivers Strong Q1 Numbers, Stock Soars
Used-car retailer America's Car-Mart (NASDAQ:CRMT) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $370.2 million. Its GAAP profit of $1.26 per share was 46.1% above analysts' consensus estimates. Is now the time to buy America's Car-Mart? Find out in our full research report. Revenue: $370.2 million vs analyst estimates of $343.5 million (1.9% year-on-year growth, 7.8% beat) EPS (GAAP): $1.26 vs analyst estimates of $0.86 (46.1% beat) Adjusted EBITDA: $33.92 million vs analyst estimates of $25.12 million (9.2% margin, 35.1% beat) Operating Margin: 8.6%, up from 5.1% in the same quarter last year Free Cash Flow was $18.44 million, up from -$12.01 million in the same quarter last year Locations: 154 at quarter end, in line with the same quarter last year Same-Store Sales fell 3.9% year on year (-5.3% in the same quarter last year) Market Capitalization: $477 million With a strong presence in the Southern and Central US, America's Car-Mart (NASDAQ:CRMT) sells used cars to budget-conscious consumers. Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. With $1.39 billion in revenue over the past 12 months, America's Car-Mart is a small retailer, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with suppliers. On the bright side, it can grow faster because it has more white space to build new stores. As you can see below, America's Car-Mart grew its sales at a solid 13% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) despite not opening many new stores. This quarter, America's Car-Mart reported modest year-on-year revenue growth of 1.9% but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, a deceleration versus the last six years. Still, this projection is healthy and implies the market sees success for its products. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. America's Car-Mart listed 154 locations in the latest quarter and has kept its store count flat over the last two years while other consumer retail businesses have opted for growth. When a retailer keeps its store footprint steady, it usually means demand is stable and it's focusing on operational efficiency to increase profitability. The change in a company's store base only tells one side of the story. The other is the performance of its existing locations and e-commerce sales, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales provides a deeper understanding of this issue because it measures organic growth at brick-and-mortar shops for at least a year. America's Car-Mart's demand has been shrinking over the last two years as its same-store sales have averaged 2.7% annual declines. This performance isn't ideal, and we'd be concerned if America's Car-Mart starts opening new stores to artificially boost revenue growth. In the latest quarter, America's Car-Mart's same-store sales fell by 3.9% year on year. This decrease represents a further deceleration from its historical levels. We hope the business can get back on track. We were impressed by how significantly America's Car-Mart blew past analysts' revenue, EPS, and adjusted operating income expectations this quarter. Zooming out, we think this quarter featured some important positives. The stock traded up 6.9% to $61.75 immediately following the results. America's Car-Mart may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts. The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers. During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors. GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relationsgeovax@ Contact: Media Contact:Jessica Starmanmedia@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Germany's BioNTech to buy CureVac to boost cancer research
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments. BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies". Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells. While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases. BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases. "This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin. It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said. Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof". BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals. Both companies are listed on the Nasdaq Composite Index. They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world. But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results. In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology. sr/fz/lth
